Investor Relations
-
Message from the Chairman and CEO
We are working to meet the expectations of our shareholders and investors by enhancing corporate value.
-
Business Results For the First Three Months of the Fiscal Year Ending March 31, 2020
IR Information
-
- Sysmex Launches its Sample Preparation System PS-10 in North America, a New Product to Make Clinical Flow Cytometry Testing More Efficient
-
- Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending March 31, 2020 (PDF：347KB)
-
- Sysmex Obtains First Manufacturing and Marketing Approval in Japan for Blood-Based RAS Gene Mutation Testing for Colorectal Cancer
-
- Posted Financial Results for the First Three Months of the Fiscal Year Ending March 31, 2020
-
- Sysmex Receives the 44th Inoue Harushige Prize
